p53 overexpression as a prognostic factor for advanced stage bladder cancer

European Journal of Cancer

Volumn 31, Issue 13-14, 1995, Pages 2243-2247

  Kuczyk, M A ^a   Bokemeyer, C ^a   Serth, J ^a   Hervatin, C ^a   Oelke, M ^a   Hofner K ^a   Tan, H K ^a   Jonas, U ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

muscle invasive bladder cancer; p53 tumour suppressor gene; pathogenesis; PCNA; prognostic factors

Indexed keywords

CISPLATIN; CYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; PROTEIN P53; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CANCER; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; RISK FACTORS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0029586840     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00443-2     Document Type: Article

References (29)

1. Biology and management of bladder cancer
2. Invasive bladder cancer: support for screening
3. Mode of presentation of invasive bladder cancer: reassessment of the problem
4. Management of invasive bladder cancer: a meticulous pelvic node dissection can make a difference
5. Long-term patient survival after cystectomy for regional metastatic transitional cell carcinoma of the bladder
6. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer
7. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma
8. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers
9. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation
10. P53 mutations in bladder cancer: correlation between immunohistochemistry (IHC), single strand conformation polymorphism (SSCP) and sequencing
11. Activating mutations for transformation by p53 produce a gene product that forms an hsc-70-p53 complex with an altered half life
12. Nuclear over-expression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression
13. P53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder
14. P53 — Immunohistochemistry as a prognostic marker in superficial bladder cancer
15. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value
16. Accumulation of nuclear p53 and tumor progression in bladder cancer
17. The prognostic value of p53 nuclear overexpression in invasive bladder cancer treated with neoadjuvant MVAC
18. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression
19. Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA): Structural conversation and the detection of a nucleolar form
20. Mutations in the p53 gene occur in diverse human tumor types
21. Molecular analysis of human bladder cancer
22. Allelic loss of chromosome 9, 11 and 17 in human bladder cancer
23. Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder
24. Molecular biology of bladder cancer
25. Identification of p53 gene mutations in bladder cancers and urine samples
26. Molecular genetic alterations in superficial and locally advanced human bladder cancer
27. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial
28. Preliminary results in invasive bladder cancer with transurethral resection, neoadjuvant chemotherapy and combined pelvic irradiation plus cisplatin chemotherapy
29. Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update